News Center

Xu huimin investigated the r&d and production base of monoclonal antibody of dongyao pharmaceutical

发布时间:2017-08-30

On the afternoon of August 23rd, xu huimin, member of the standing committee of suzhou municipal party committee and secretary of the party working committee of suzhou industrial park visited our company for investigation. Zhu jiang, office director of the industrial and administrative committee of the park, sun yangcheng, director of the economic development committee, liu hua, director of the China merchants bureau, tao jun, deputy director of the market supervision bureau and other leaders of relevant departments accompanied the investigation. Company general manager huang chunying, deputy general manager liu jun and other company senior leaders accompanied.  

Ms. Huang chunying, general manager, first welcomed and thanked Mr. Xu and his delegation for their visit, then introduced the recent development of the company and focused on the report of the monoclonal antibody r&d and production base under construction in the second phase. Single resistance to drug research and development production base construction began in October 2016, for the production of sheet resistance to drugs and antibody coupling, with 5 2000 l scale of cell culture production line, production capacity of all upgrade (10000 l), after the completion will be the domestic biological pharmaceutical industry one of the largest production base of research and development, can meet the biological medicine from upstream r&d, pilot production, clinical trial drug and the demand of commercial production.  

On the afternoon of August 23rd, xu huimin, member of the standing committee of suzhou municipal party committee and secretary of the party working committee of suzhou industrial park visited our company for investigation. Zhu jiang, office director of the industrial and administrative committee of the park, sun yangcheng, director of the economic development committee, liu hua, director of the China merchants bureau, tao jun, deputy director of the market supervision bureau and other leaders of relevant departments accompanied the investigation. Company general manager huang chunying, deputy general manager liu jun and other company senior leaders accompanied.  

Ms. Huang chunying, general manager, first welcomed and thanked Mr. Xu and his delegation for their visit, then introduced the recent development of the company and focused on the report of the monoclonal antibody r&d and production base under construction in the second phase. Single resistance to drug research and development production base construction began in October 2016, for the production of sheet resistance to drugs and antibody coupling, with 5 2000 l scale of cell culture production line, production capacity of all upgrade (10000 l), after the completion will be the domestic biological pharmaceutical industry one of the largest production base of research and development, can meet the biological medicine from upstream r&d, pilot production, clinical trial drug and the demand of commercial production.  


 

Secretary xu expressed his appreciation and affirmation to the company's achievements. After learning that the second phase of the company's project will be used for the production of monoclonal antibodies and antibody-coupled drugs, secretary xu said that the park is now doing its best to develop the biomedical industry, and will pay close attention to enterprises and continue to vigorously support the development of enterprises. In the investigation, secretary xu also asked the actual development of the company in detail, and instructed the relevant departments to implement as soon as possible, solve.  

The investigation was conducted by the leaders of the park to directly connect with the enterprise, understand the current development situation of the enterprise and solve the actual development needs of the enterprise. It reflected the concept of "pro-business and pro-business" of the park government, and strengthened the determination and confidence of TOT to "take root in suzhou and the park and go global".   

Secretary xu expressed his appreciation and affirmation to the company's achievements. After learning that the second phase of the company's project will be used for the production of monoclonal antibodies and antibody-coupled drugs, secretary xu said that the park is now doing its best to develop the biomedical industry, and will pay close attention to enterprises and continue to vigorously support the development of enterprises. In the investigation, secretary xu also asked the actual development of the company in detail, and instructed the relevant departments to implement as soon as possible, solve.  

The investigation was conducted by the leaders of the park to directly connect with the enterprise, understand the current development situation of the enterprise and solve the actual development needs of the enterprise. It reflected the concept of "pro-business and pro-business" of the park government, and strengthened the determination and confidence of TOT to "take root in suzhou and the park and go global".